155271-71-9

Basic information

• Product Name: 8-[(E)-2-(4-bromophenyl)ethenyl]-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione
• CAS NO: 155271-71-9
• Molecular Formula: C₁₈H₁₉BrN₄O₂
• Molecular Weight: 403.2731
• Mol File: 155271-71-9.mol

Chemical Properties

• Boiling Point: 585.4°C at 760 mmHg
• Flash Point: 307.9°C
• Density: 1.44g/cm³
• Vapor Pressure: 1.09E-13mmHg at 25°C
• Refractive Index: 1.649
• CAS DataBase Reference: 8-[(E)-2-(4-bromophenyl)ethenyl]-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 8-[(E)-2-(4-bromophenyl)ethenyl]-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione(155271-71-9)
• EPA Substance Registry System: 8-[(E)-2-(4-bromophenyl)ethenyl]-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione(155271-71-9)

Safety Data

• Hazardous Substances Data: 155271-71-9(Hazardous Substances Data)

Upstream product

• 155271-70-8 (E)-8-(4-bromostyryl)-1,3-diethyl-1H-purine-2,6(3H,7H)-dione 
• 74-88-4 methyl iodide 
• 52998-22-8 5,6-diamino-1,3-diethyluracil 
• 1200-07-3 trans-4-bromocinnamic acid 

Relevant articles and documents

8-substituted styryl xanthine derivative and application thereof

The invention discloses an 8-substituted styryl xanthine derivative and application thereof, particularly relates to a novel 8-substituted styryl xanthine derivative and a pharmaceutical composition containing the compound, and can be used as a selective adenosine A2A receptor antagonist. The invention also relates to a method for preparing the compound and the pharmaceutical composition and application of the compound and the pharmaceutical composition in preparation of drugs for treating adenosine A2A receptor related diseases, especially Parkinson's disease.

The adenosine A2A antagonistic properties of selected C8-substituted xanthines

The adenosine A2A receptor is considered to be an important target for the development of new therapies for Parkinson's disease. Several antagonists of the A2A receptor have entered clinical trials for this purpose and many research

Antidepressants

The present invention relates to an antidepressant containing as an active ingredient a xanthine derivative or a pharmaceutically acceptable salt thereof, the xanthine derivative being represented by Formula (I) : STR1 in which R1, R2, and R3 represent independently hydrogen, lower alkyl, lower alkenyl; R4 represents cycloalkyl, --(CH2)n --R5 (in which R5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4), or STR2 (in which Y1 and Y2 represent independently hydrogen, halogen or lower alkyl; and Z represents substituted or unsubstituted aryl, STR3 (in which R6 represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m represents an integer of 1 to 3), or a substituted or unsubstituted heterocyclic group); and X1 and X2 represent independently O or S.

Therapeutic agent for Parkinson's disease

Agents for the treatment of Parkinson''s disease contain, as an active ingredient, a xanthine derivative or a pharmaceutically acceptable salt thereof. The xanthine derivative is represented by the formula: STR1 in which R 1, R 2 are R 3 are independently hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and R 4 represents cycloalkyl, --(CH 2) n --R 5 (in which R 5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4), or STR2 in which Y 1 and Y 2 represent independently hydrogen, halogen, or lower alkyl; and Z represents substituted or unsubstituted aryl, STR3 in which R 6 represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m represents an integer of 1 to 4, or a substituted or unsubstituted heterocyclic group; and X 1 and X 2 represent independently O or S.